- Home
- NTIC vs CRDF Comparison
NTIC vs CRDF Comparison
Compare NTIC & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIC
- CRDF
- Stock Information
- Founded
- NTIC 1970
- CRDF 1999
- Country
- NTIC United States
- CRDF United States
- Employees
- NTIC N/A
- CRDF N/A
- Industry
- NTIC Industrial Specialties
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NTIC Industrials
- CRDF Health Care
- Exchange
- NTIC Nasdaq
- CRDF Nasdaq
- Market Cap
- NTIC 116.9M
- CRDF 133.5M
- IPO Year
- NTIC N/A
- CRDF N/A
- Fundamental
- Price
- NTIC $14.32
- CRDF $5.35
- Analyst Decision
- NTIC Buy
- CRDF Strong Buy
- Analyst Count
- NTIC 1
- CRDF 3
- Target Price
- NTIC $20.00
- CRDF $10.33
- AVG Volume (30 Days)
- NTIC 23.7K
- CRDF 3.9M
- Earning Date
- NTIC 01-09-2025
- CRDF 11-07-2024
- Dividend Yield
- NTIC 1.94%
- CRDF N/A
- EPS Growth
- NTIC 83.33
- CRDF N/A
- EPS
- NTIC 0.55
- CRDF N/A
- Revenue
- NTIC $85,059,517.00
- CRDF $688,000.00
- Revenue This Year
- NTIC $11.04
- CRDF $23.78
- Revenue Next Year
- NTIC $8.10
- CRDF N/A
- P/E Ratio
- NTIC $26.22
- CRDF N/A
- Revenue Growth
- NTIC 6.45
- CRDF 49.57
- 52 Week Low
- NTIC $11.06
- CRDF $1.30
- 52 Week High
- NTIC $19.63
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- NTIC 58.39
- CRDF 77.18
- Support Level
- NTIC $13.44
- CRDF $3.06
- Resistance Level
- NTIC $14.49
- CRDF $4.20
- Average True Range (ATR)
- NTIC 0.48
- CRDF 0.42
- MACD
- NTIC 0.04
- CRDF 0.26
- Stochastic Oscillator
- NTIC 89.31
- CRDF 91.43
About NTIC Northern Technologies International Corporation
Northern Technologies International Corp, or NTIC is a United States-based firm that develops and markets environmentally beneficial products and services world-wide either directly or through a network of joint ventures, distributors, and agents. It operates through two segments which include ZERUST products and services and Nature-Tec products. Its main business is providing corrosion prevention solutions that are marketed under the ZERUST brand. The company also sells a portfolio of bio-based and biodegradable (compostable) polymer resin compounds and finished products marketed under the Nature-Tec brand. The ZERUST brand generates a vast majority of the revenue for the company.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").